Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2026SHILAP Revista de lepidopterologíaOpen Access

Bispecific and trispecific antibodies in atopic dermatitis: a review of the emerging clinical pipeline

View Full Paper
Ask AI
Bookmark
Share

Authors

GAGili Amid-TobyOAOmar AlaniCBChristopher G. Bunick

Discussion

Loading...

Member takes

Overview

This review highlights emerging multi-specific biologics in atopic dermatitis, suggesting advancements in treatment outcomes.

Key Points

  • The review examines the development and potential of bispecific and trispecific antibodies in treating atopic dermatitis.
  • Reviewed clinical data on emerging biologics targeting multiple cytokine pathways.
  • Discussed various bispecific and trispecific antibody constructs and their mechanisms.
  • Analyzed real-world effectiveness of monospecific biologics versus multi-target therapies.
  • Current monoclonal therapies often fail to achieve EASI 90 scores in most patients.
  • Janus kinase inhibitors show superior results in achieving clearance and itch control.
  • Emerging multi-target designs indicated potential for improved treatment outcomes and longer dosing intervals.

Cite This Study

Amid-Toby et al. (2026) studied this question.

synapsesocial.com/papers/69e470a4010ef96374d8d8e1https://doi.org/10.3389/fddsv.2026.1766021
View Full Paper
Ask AI
Bookmark
Share